Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib vs Chemotherapy with Icotinib Maintenance in EGFR+ Lung Adenocarcinoma
NCT01665417Phase 4Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Aug 2012
- Primary completion
- Jul 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of icotinib in lung adenocarcinoma (3 arms), sponsored by Betta Pharmaceuticals. Primary endpoint: Progression-free survival at 8 months. Status: unknown.
02
Drugs
icotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT01665417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01665417.